Labcorp (LH) said Wednesday it launched a blood-based biomarker test called pTau-217/Beta Amyloid 42 Ratio to aid in the diagnosis of Alzheimer's disease.
The blood test confirm the presence of amyloid pathology, which is associated with the disease, the company said.
Labcorp said the test offers a sensitivity and specificity of 95%, which is "substantially equivalent" to the performance of amyloid positron emission tomography imaging and cerebrospinal fluid testing.
The test can be used in clinical trials in addition to clinical patient care, the company said.
Price: 236.59, Change: +3.94, Percent Change: +1.69
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。